These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 32795588)

  • 1. Identification of whole blood gene expressions correlated with responsiveness to benralizumab.
    Nakajima M; Matsuyama M; Arai N; Yamada H; Hyodo K; Nonaka M; Kitazawa H; Yoshida K; Shigemasa R; Morishima Y; Kiwamoto T; Masuko H; Ishii Y; Muratani M; Saito T; Hizawa N
    J Allergy Clin Immunol; 2021 Feb; 147(2):772-775. PubMed ID: 32795588
    [No Abstract]   [Full Text] [Related]  

  • 2. Benralizumab in Real Life.
    Miralles López JC; Escudero Pastor AI; Carbonell Martínez A; Navarro Garrido C; Bonilla Pacheco Y; Petrik Petrik Y
    J Investig Allergol Clin Immunol; 2021 Feb; 31(1):87-88. PubMed ID: 32573458
    [No Abstract]   [Full Text] [Related]  

  • 3. Severe uncontrolled eosinophilic asthma, which responded to benralizumab after failure to respond to mepolizumab.
    Kurosawa M; Sutoh E
    Ann Allergy Asthma Immunol; 2019 Apr; 122(4):431-433. PubMed ID: 30578859
    [No Abstract]   [Full Text] [Related]  

  • 4. Benralizumab strongly reduces blood basophils in severe eosinophilic asthma.
    Lommatzsch M; Marchewski H; Schwefel G; Stoll P; Virchow JC; Bratke K
    Clin Exp Allergy; 2020 Nov; 50(11):1267-1269. PubMed ID: 32762056
    [No Abstract]   [Full Text] [Related]  

  • 5. Successful management of eosinophilic chronic rhinosinusitis complicated by severe asthma using dupilumab, following negative initial results with benralizumab.
    Suzaki I; Tanaka A; Hirano K; Arai S; Kobayashi H
    Allergol Int; 2021 Jan; 70(1):150-152. PubMed ID: 32507512
    [No Abstract]   [Full Text] [Related]  

  • 6. The clinical profile of benralizumab in the management of severe eosinophilic asthma.
    Menzella F; Lusuardi M; Galeone C; Facciolongo N; Zucchi L
    Ther Adv Respir Dis; 2016 Dec; 10(6):534-548. PubMed ID: 27612492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-Life effects of benralizumab on exacerbation number and lung hyperinflation in atopic patients with severe eosinophilic asthma.
    Pelaia C; Busceti MT; Crimi C; Carpagnano GE; Lombardo N; Terracciano R; Vatrella A; Pelaia G
    Biomed Pharmacother; 2020 Sep; 129():110444. PubMed ID: 32593131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypereosinophilia with systemic manifestations under dupilumab and possibility of dual benralizumab and dupilumab therapy in patients with asthma and CRSwNP.
    Briegel I; Felicio-Briegel A; Mertsch P; Kneidinger N; Haubner F; Milger K
    J Allergy Clin Immunol Pract; 2021 Dec; 9(12):4477-4479. PubMed ID: 34384930
    [No Abstract]   [Full Text] [Related]  

  • 9. Early decreases in blood eosinophil levels with reslizumab.
    Chanez P; McDonald M; Garin M; Murphy K
    J Allergy Clin Immunol; 2019 Apr; 143(4):1653-1655. PubMed ID: 30654046
    [No Abstract]   [Full Text] [Related]  

  • 10. [Severe refractory eosinophilic asthma].
    Jäger-Becker D
    MMW Fortschr Med; 2016 Feb; 158(3):67. PubMed ID: 27119709
    [No Abstract]   [Full Text] [Related]  

  • 11. Real-life rapidity of benralizumab effects in patients with severe allergic eosinophilic asthma: Assessment of blood eosinophils, symptom control, lung function and oral corticosteroid intake after the first drug dose.
    Pelaia C; Busceti MT; Vatrella A; Rago GF; Crimi C; Terracciano R; Pelaia G
    Pulm Pharmacol Ther; 2019 Oct; 58():101830. PubMed ID: 31344472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Benralizumab, a Monoclonal Antibody against IL-5Rα, in Uncontrolled Eosinophilic Asthma.
    Khorasanizadeh M; Eskian M; Assa'ad AH; Camargo CA; Rezaei N
    Int Rev Immunol; 2016 Jul; 35(4):294-311. PubMed ID: 27119985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of benralizumab for eosinophilic asthma: A systematic review and meta-analysis of randomized controlled trials.
    Tian BP; Zhang GS; Lou J; Zhou HB; Cui W
    J Asthma; 2018 Sep; 55(9):956-965. PubMed ID: 29211545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reverse butterfly pattern image with eosinophilia: Effective treatment with benralizumab-A case report.
    Ben-David Y; Bentur L; Gur M; Ilivitzki A; Gut G; Toukan Y; Nir V; Shallufi G; Bar-Yoseph R
    Pediatr Pulmonol; 2021 Aug; 56(8):2736-2739. PubMed ID: 34077999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reslizumab (Cinqair) for severe eosinophilic asthma.
    Med Lett Drugs Ther; 2016 Jun; 58(1497):81-2. PubMed ID: 27305070
    [No Abstract]   [Full Text] [Related]  

  • 16. Reslizumab Compared with Benralizumab in Patients with Eosinophilic Asthma: A Systematic Literature Review and Network Meta-Analysis.
    Casale TB; Pacou M; Mesana L; Farge G; Sun SX; Castro M
    J Allergy Clin Immunol Pract; 2019 Jan; 7(1):122-130.e1. PubMed ID: 30217529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe asthma with eosinophilic gastroenteritis effectively managed by mepolizumab and omalizumab.
    Han D; Lee JK
    Ann Allergy Asthma Immunol; 2018 Dec; 121(6):742-743. PubMed ID: 30056148
    [No Abstract]   [Full Text] [Related]  

  • 18. The Use of Benralizumab in the Treatment of Near-Fatal Asthma: A New Approach.
    Ramakrishnan S; Camp JR; Vijayakumar B; Hardinge FM; Downs ML; Russell REK; Pavord ID; Bafadhel M
    Am J Respir Crit Care Med; 2020 Jun; 201(11):1441-1443. PubMed ID: 32023077
    [No Abstract]   [Full Text] [Related]  

  • 19. Benralizumab for the treatment of asthma.
    Matera MG; Rogliani P; Calzetta L; Canonica GW; Cazzola M
    Drugs Today (Barc); 2017 Dec; 53(12):633-645. PubMed ID: 29517082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Forced oscillation technique as method to document and monitor the efficacy of mepolizumab in treating severe eosinophilic asthma.
    Antonicelli L; Tontini C; Marchionni A; Lucchetti B; Garritani MS; Bilò MB
    Allergy; 2020 Feb; 75(2):433-436. PubMed ID: 31166020
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.